Ono Pharmaceutical Co., Ltd. (TYO:4528)
2,417.50
+1.50 (0.06%)
Aug 13, 2026, 3:30 PM JST
Ono Pharmaceutical Revenue
Ono Pharmaceutical had revenue of 116.16B JPY in the quarter ending June 30, 2026, a decrease of -8.92%. This brings the company's revenue in the last twelve months to 504.41B, up 1.55% year-over-year. In the fiscal year ending March 31, 2026, Ono Pharmaceutical had annual revenue of 515.79B with 5.94% growth.
Revenue (ttm)
504.41B
Revenue Growth
+1.55%
P/S Ratio
2.25
Revenue / Employee
119.93M
Employees
4,206
Market Cap
1.14T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 515.79B | 28.91B | 5.94% |
| Mar 31, 2025 | 486.87B | -15.80B | -3.14% |
| Mar 31, 2024 | 502.67B | 55.49B | 12.41% |
| Mar 31, 2023 | 447.19B | 85.83B | 23.75% |
| Mar 31, 2022 | 361.36B | 52.08B | 16.84% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Otsuka Holdings | 2.62T |
| Astellas Pharma | 2.27T |
| Daiichi Sankyo Company | 2.22T |
| Chugai Pharmaceutical | 1.34T |
| Kyowa Kirin | 529.80B |
| Santen Pharmaceutical | 291.84B |
| JCR Pharmaceuticals | 41.45B |
| Perseus Proteomics | 135.00M |
Ono Pharmaceutical News
- 7 days ago - Ono Pharma Enters into a Drug Discovery Partnership with Mediar Therapeutics to Create Novel Antibody Therapeutics for Fibro-inflammatory Diseases - Business Wire
- 13 days ago - Ono Pharmaceutical Quarterly report: Q1 2027 - Filings
- 13 days ago - Ono Pharmaceutical Slides: Q1 2027 - Filings
- 15 days ago - Ono Pharmaceutical Partners with Phylo to Enhance Drug Discovery with AI - GuruFocus
- 15 days ago - Ono Pharmaceutical partners with Phylo to embed agentic AI with every discovery scientist - PRNewsWire
- 2 months ago - Ono Pharmaceutical Slides: Investor presentation - Filings
- 2 months ago - Ono Pharma Announces Oral Presentation of New Data from the Phase 2 Clinical Study of ONO-4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting - Business Wire
- 3 months ago - Ono Pharmaceutical Quarterly report: Q4 2026 - Filings